Abstract
Whole genome sequencing (WGS) is increasingly used to map the spread and transmission dynamics of human pathogens, especially in nosocomial settings. A limiting factor for more widespread adoption of WGS for infection prevention practices is the availability of standardized tools for genome analysis. Here we present PathoSPOT, which integrates genomic and electronic medical record (EMR) data for rapid detection of nosocomial outbreaks and analysis of epidemiological timelines. To demonstrate its capabilities we analyzed complete genomes obtained from long-read sequencing of 197 invasive MRSA (bacteremia) cases from two hospitals during a two-year period. PathoSPOT identified 8 clonal clusters that had not been identified by epidemiological data, encompassing 33 patients (16.8%). The largest cluster was consistent with an outbreak of a hospital-associated ST105 MRSA clone among 16 adult patients in multiple wards. Timeline and location data suggested that an early outbreak event led to infection and long-term colonization of multiple cases, followed by transmissions to other patients during subsequent hospitalizations. Overall, we find that PathoSPOT can detect outbreaks that are not readily apparent from epidemiological data and contribute to morbidity and mortality. When applied as part of comprehensive ‘real-time’ sequencing-based surveillance, PathoSPOT may play an important role in understanding the complexities of pathogen transmission dynamics and enable timely interventions.
Competing Interest Statement
Robert Sebra is VP of Technology Development and a stockholder at Sema4, a Mount Sinai Venture. This work, however, was conducted solely at Icahn School of Medicine at Mount Sinai.
Funding Statement
This research was supported in part by R01 AI119145 (H.v.B.), the Icahn Institute for Genomics and Data Science (A.K.), the CTSA/NCATS KL2 Program (KL2TR001435, Icahn School of Medicine at Mount Sinai; D.R.A), and the New York State Department of Health Empire Clinical Research Investigator Program (Awarded to Judith A. Aberg, Icahn School of Medicine at Mount Sinai; D.R.A.) and F30 AI122673 (T.R.P.). The Research reported in this paper was supported by the Office of Research Infrastructure of the National Institutes of Health (NIH) under award numbers S10OD018522 and S10OD026880 as well as institutional funds. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# These authors are co-senior authors on this work
Data Availability
All study data is available at https://www.pathospot.org.
